Trial intelligence / Profile preview

Sinanumin versus triamcinolone acetonide for recurrent oral aphthous ulcers in Behcet's disease

IRCT20190308042966N1Phase 3Completed

Sponsor
Mashhad University of Medical Sciences
Start
Dec 2019
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, randomised, open-label trial of triamcinolone acetonide, colchicine and curcumin in Behçet's disease (BD) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Number of ulcer, Size of ulcer and 2 more. Started Dec 2019; status: completed.

02

Drugs

triamcinolone acetonidecolchicinecurcumin
03

Conditions

Behçet's disease (BD)

Beyond the preview

Go deeper on IRCT20190308042966N1.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on IRCT20190308042966N1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call